Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Health resource utilization and the economic burden of patients with wet age-related macular degeneration in Thailand.

Dilokthornsakul P, Chaiyakunapruk N, Ruamviboonsuk P, Ratanasukon M, Ausayakhun S, Tungsomeroengwong A, Pokawattana N, Chanatittarat C.

Int J Ophthalmol. 2014 Feb 18;7(1):145-51. doi: 10.3980/j.issn.2222-3959.2014.01.27. eCollection 2014.

2.

Economic burden of bilateral neovascular age-related macular degeneration: multi-country observational study.

Cruess AF, Zlateva G, Xu X, Soubrane G, Pauleikhoff D, Lotery A, Mones J, Buggage R, Schaefer C, Knight T, Goss TF.

Pharmacoeconomics. 2008;26(1):57-73.

PMID:
18088159
3.

Routine eye examinations for persons 20-64 years of age: an evidence-based analysis.

Health Quality Ontario..

Ont Health Technol Assess Ser. 2006;6(15):1-81. Epub 2006 Jul 1.

4.

Financial burden and quality of life of informal caregivers of patients with wet age-related macular degeneration.

Weyer-Wendl H, Walter P.

Health Econ Rev. 2016 Dec;6(1):37. doi: 10.1186/s13561-016-0116-4. Epub 2016 Aug 26.

5.

The burden of age-related macular degeneration.

Schmier JK, Jones ML, Halpern MT.

Pharmacoeconomics. 2006;24(4):319-34. Review.

PMID:
16605279
6.

Burden of illness of bilateral neovascular age-related macular degeneration in Spain.

Ruiz-Moreno JM, Coco RM, García-Arumí J, Xu X, Zlateva G.

Curr Med Res Opin. 2008 Jul;24(7):2103-11. doi: 10.1185/03007990802214300 . Epub 2008 Jun 10.

PMID:
18547463
7.

The burden of age-related macular degeneration: results of a cohort study in two French referral centres.

Bonastre J, Le Pen C, Soubrane G, Quentel G.

Pharmacoeconomics. 2003;21(3):181-90.

PMID:
12558468
8.

[Neovascular age-related macular degeneration in Germany. Encroachment on the quality of life and the financial implications].

Pauleikhoff D, Scheider A, Wiedmann P, Gelisken F, Scholl HP, Roider I, Mohr A, Zlateva G, Xu X.

Ophthalmologe. 2009 Mar;106(3):242-51. doi: 10.1007/s00347-008-1797-9. German.

PMID:
18709375
9.

Verteporfin photodynamic therapy for neovascular age-related macular degeneration: cohort study for the UK.

Reeves BC, Harding SP, Langham J, Grieve R, Tomlin K, Walker J, Guerriero C, Carpenter J, Patton WP, Muldrew KA, Peto T, Chakravarthy U.

Health Technol Assess. 2012;16(6):i-xii, 1-200. doi: 10.3310/hta16060.

10.

SOCIETAL COSTS ASSOCIATED WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION IN THE UNITED STATES.

Brown MM, Brown GC, Lieske HB, Tran I, Turpcu A, Colman S.

Retina. 2016 Feb;36(2):285-98. doi: 10.1097/IAE.0000000000000717.

PMID:
26428606
11.

Optical coherence tomography for age-related macular degeneration and diabetic macular edema: an evidence-based analysis.

Health Quality Ontario..

Ont Health Technol Assess Ser. 2009;9(13):1-22. Epub 2009 Sep 1.

12.

Association between visual acuity and medical and non-medical costs in patients with wet age-related macular degeneration in France, Germany and Italy.

Bandello F, Augustin A, Sahel JA, Benhaddi H, Negrini C, Hieke K, Berdeaux GH; MICMAC (MICro-economics of MACular degeneration) Study Group..

Drugs Aging. 2008;25(3):255-68.

PMID:
18331076
13.

Burden of illness of neovascular age-related macular degeneration in Canada.

Cruess A, Zlateva G, Xu X, Rochon S.

Can J Ophthalmol. 2007 Dec;42(6):836-43.

PMID:
18026200
14.

Economic burden of schizophrenia: empirical analyses from a survey in Thailand.

Phanthunane P, Whiteford H, Vos T, Bertram M.

J Ment Health Policy Econ. 2012 Mar;15(1):25-32.

PMID:
22611090
15.

[Financial burden of hepatitis B-related diseases and factors influencing the costs in Shenzhen, China].

Liang S, Zhang SX, Ma QS, Xiao HW, Lü QY, Xie X, Mei SJ, Hu DS, Zhou BP, Li B, Chen JF, Cui FQ, Wang FZ, Liang XF.

Zhonghua Liu Xing Bing Xue Za Zhi. 2010 Dec;31(12):1340-5. Chinese.

PMID:
21223660
16.

Ranibizumab and pegaptanib for the treatment of age-related macular degeneration: a systematic review and economic evaluation.

Colquitt JL, Jones J, Tan SC, Takeda A, Clegg AJ, Price A.

Health Technol Assess. 2008 May;12(16):iii-iv, ix-201. Review.

17.

Administrative claims analysis of all-cause annual costs of care and resource utilization by age category for ulcerative colitis patients.

Bickston SJ, Waters HC, Dabbous O, Tang BI, Rahman M.

J Manag Care Pharm. 2008 May;14(4):352-62.

18.

Incremental 1-year medical resource utilization and costs for patients with herpes zoster from a set of US health plans.

White RR, Lenhart G, Singhal PK, Insinga RP, Itzler RF, Pellissier JM, Segraves AW.

Pharmacoeconomics. 2009;27(9):781-92. doi: 10.2165/11317560-000000000-00000.

PMID:
19757871
19.

Economic burden in direct costs of concomitant chronic obstructive pulmonary disease and asthma in a Medicare Advantage population.

Blanchette CM, Gutierrez B, Ory C, Chang E, Akazawa M.

J Manag Care Pharm. 2008 Mar;14(2):176-85.

20.

Aflibercept for neovascular age-related macular degeneration.

Sarwar S, Clearfield E, Soliman MK, Sadiq MA, Baldwin AJ, Hanout M, Agarwal A, Sepah YJ, Do DV, Nguyen QD.

Cochrane Database Syst Rev. 2016 Feb 8;2:CD011346. doi: 10.1002/14651858.CD011346.pub2. Review.

Supplemental Content

Support Center